Aktis Oncology, Inc. (AKTS) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Aktis Oncology, Inc. (AKTS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.11B, listed on NASDAQ, employing roughly 79 people, carrying a beta of 1.10 to the broader market. Aktis Oncology, Inc. Led by Matthew Roden, public since 2026-01-09.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for AKTS as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →